Manufacturing. Upon EISAI’s request, [[EPIZYME:Organization]] shall, as part of the transition plan to be mutually agreed by the Parties under clause (e) below, at EISAI’s expense, transfer to EISAI (or its designee) any processes, documents, materials and other Know-How, to the extent the foregoing is Controlled by [[EPIZYME:Organization]] as of the effective date of termination and used in the Manufacture of Licensed Products in the Field as they exist as of the date of termination; provided that, upon EISAI’s request and pursuant to a supply agreement to be negotiated in good faith by the Parties, at a purchase price equal to [[EPIZYME:Organization]]’s Cost of Goods for clinical supplies and ​ of [[EPIZYME:Organization]]’s Cost of Goods for commercial supplies, supply EISAI with clinical and commercial quantities of the Licensed Products for the [[EPIZYME:Organization]] Territory in the dosage strengths, formulations and presentations under Development or being Commercialized by [[EPIZYME:Organization]], in either case, as of the effective date of termination, until the earlier of: # ​ months after the effective date of termination; or # establishment by EISAI of an alternative supply for such Licensed Products on commercially reasonable terms.

Manufacturing. Upon [[EPIZYME:Organization]]’s request, EISAI shall, as part of the transition plan to be mutually agreed by the Parties under [clause (c) above], at [[EPIZYME:Organization]]’s expense, transfer to [[EPIZYME:Organization]] (or its designee) any processes, documents, materials and other Know-How, to the extent the foregoing is Controlled by EISAI as of the effective date of termination and used in the Manufacture of Licensed Products in the Field as they exist as of the date of termination.